Recombinant Human ProSAAS protein (denatured) (ab174456)
Key features and details
- Expression system: Escherichia coli
- Purity: > 85% SDS-PAGE
- Tags: His tag N-Terminus
- Suitable for: SDS-PAGE
Description
-
Product name
Recombinant Human ProSAAS protein (denatured)
See all ProSAAS proteins and peptides -
Purity
> 85 % SDS-PAGE. -
Expression system
Escherichia coli -
Accession
-
Protein length
Full length protein -
Animal free
No -
Nature
Recombinant -
-
Species
Human -
Sequence
MGSSHHHHHHSSGLVPRGSHMGSMARPVKEPRGLSAASPPLAETGAPRRF RRSVPRGEAAGAVQELARALAHLLEAERQERARAEAQEAEDQQARVLAQL LRVWGAPRNSDPALGLDDDPDAPAAQLARALLRARLDPAALAAQLVPAPV PAAALRPRPPVYDDGPAGPDAEEAGDETPDVDPELLRYLLGRILAGSADS EGVAAPRRLRRAADHDVGSELPPEGVLGALLRVKRLETPAPQVPARRLLP P -
Predicted molecular weight
27 kDa including tags -
Amino acids
34 to 260 -
Tags
His tag N-Terminus -
Additional sequence information
NCBI Accession No.: NP_037403
-
-
Description
Recombinant Human ProSAAS protein
Associated products
-
Related Products
Specifications
Our Abpromise guarantee covers the use of ab174456 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
-
Applications
SDS-PAGE
-
Form
Liquid -
Concentration information loading...
Preparation and Storage
-
Stability and Storage
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle.
pH: 8.00
Constituents: 2.4% Urea, 10% Glycerol (glycerin, glycerine), 0.32% Tris HCl
General Info
-
Alternative names
- b-LEN
- b-PEN-LEN
- b-SAAS
see all -
Function
May function in the control of the neuroendocrine secretory pathway. Proposed be a specific endogenous inhibitor of PCSK1. ProSAAS and Big PEN-LEN, both containing the C-terminal inhibitory domain, but not the further processed peptides reduce PCSK1 activity in the endoplasmic reticulum and Golgi. It reduces the activity of the 84 kDa form but not the autocatalytically derived 66 kDa form of PCSK1. Subsequent processing of proSAAS may eliminate the inhibition. Slows down convertase-mediated processing of proopiomelanocortin and proenkephalin. May control the intracellular timing of PCSK1 rather than its total level of activity. The function of the processed secreted peptides is not known. -
Tissue specificity
Expressed in brain and pancreas. -
Domain
ProSAAS(1-180) increases secretion of enzymatically inactive PCSK1.
The C-terminal inhibitory domain is involved in inhibtion of PCSK1. It corresponds to the probable processing intermediate Big PEN-LEN, binds to PCSK1 in vitro and contains the hexapeptide L-L-R-V-K-R, which, as a synthetic peptide, is sufficient for PCSK1 inhibition. -
Post-translational
modificationsProteolytically cleaved in the Golgi.
O-glycosylated with a core 1 or possibly core 8 glycan. -
Cellular localization
Secreted. Golgi apparatus > trans-Golgi network. A N-terminal processed peptide, probably Big SAAS or Little SAAS, is accumulated in cytoplasmic protein tau deposits in frontotemporal dementia and parkinsonism linked to chromosome 17 (Pick disease), Alzheimer disease and amyotrophic lateral sclerosis-parkinsonism/dementia complex 1. - Information by UniProt
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
Datasheets and documents
-
SDS download
-
Datasheet download
References (0)
ab174456 has not yet been referenced specifically in any publications.